ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncol...( SAN DIEGO June 3 /- ADVENTRX Phar...),Health

SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFactor(R), for the treatment of advanced breast cancer at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL. CoFactor plus 5-FU (5-Fluorouracil) was determined to be a safe, well-tolerated and active treatment regimen in advanced breast cancer patients who are Herceptin receptor (Her2/neu) negative and who have failed prior taxane and anthracycline therapies. Data available from 31 patients indicated a 23% objective response rate with CoFactor plus 5-FU based on investigators' assessments. Objective response rate was based on the number of complete responses and partial responses observed in this study.

The poster presentation, entitled "5,10 methylenetetrahydrofolic acid with 5-fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase 2 study," was presented by Dr. Joachim P.H. Schupp, Vice President of Medical Affairs on June 2, 2008.

Historically, capecitabine (Xeloda(R)), a widely-used treatment for advanced breast cancer, has demonstrated response rates between 14% and 26% when studied as monotherapy in patients with advanced breast cancer who failed prior treatment with anthracyclines and taxanes. In this well-defined study population, two recently published, Phase 3 clinical trials, where capecitabine was the approved therapy, demonstrated response rates of 14% for capecitabine alone compared with 35% for capecitabine in combination with ixabepil
'/>"/>